Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2226 - 2250 of 14991 in total

Teniposide

Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic...
Approved
Matched Description: … Teniposide acts primarily in the G2 and S phases of the cycle. ... Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. ... This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Cerliponase alfa

Cerliponase alfa is an enzyme replacement treatment for a specific form of Batten disease. It was the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl...
Approved
Investigational
Matched Description: … treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Halcinonide

Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of...
Approved
Investigational
Withdrawn
Matched Description: … of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. ... Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations …

Nomegestrol

Nomegestrol is an ingredient in the EMA-authorised product Zoely.
Approved
Matched Categories: … nomegestrol and estrogen ... nomegestrol and estradiol ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …

Clobetasol

Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Approved
Experimental
Investigational
Matched Description: … Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids …
Matched Categories: … clobetasol and antibiotics ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Binimetinib

Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib.[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of Encorafenib and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients...
Approved
Investigational
Matched Description: … ] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with ... Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase ... [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Xamoterol

Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.
Approved
Matched Description: … Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function …

Dexrazoxane

An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and...
Approved
Withdrawn
Matched Description: … prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. ... [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the …

Thiotepa

N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow...
Approved
Investigational
Matched Description: … It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Istradefylline

Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A2A receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline...
Approved
Investigational
Matched Description: … [A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's …

Relatlimab

Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and ... has garnered interest in the treatment of a variety of cancers, including leukemia[A246160] and melanoma …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Idecabtagene vicleucel

Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal...
Approved
Matched Description: … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from ... known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and ... vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …

NADH

NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by...
Approved
Nutraceutical
Matched Iupac: … [(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid …
Matched Description: … electron carrier by being alternately oxidized (NAD+) and reduced (NADH). ... It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an ... NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide …
Matched Categories: … Enzymes and Coenzymes ... Nucleic Acids, Nucleotides, and Nucleosides …

Sacrosidase

Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients...
Approved
Matched Description: … People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues ... Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet ... metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Elosulfase alfa

Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™. The recommended dose is 2 mg per kg given intravenously over...
Approved
Investigational
Matched Description: … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Chondroitinases and Chondroitin Lyases …

Pegvisomant

Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Approved
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Anterior Pituitary Lobe Hormones and Analogues ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Insulin icodec

Insulin icodec is an ultra long-acting basal insulin analogue.
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Tibolone

Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha . Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic...
Approved
Investigational
Matched Description: … produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and ... Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the ... been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists ... Estrogens, Antiestrogens, and Estrogen Agonist-Antagonists …

Amivantamab

Amivantamab, also known as JNJ-61186372, is an anti-EGFR-MET bispecific antibody, derived from Chinese hamster ovary cells, approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose...
Approved
Investigational
Matched Description: … FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and ... [A235103,L34193] Patients with NSCLC often develop resistance to drugs that target EGFR and MET individually ... Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Somapacitan

Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval...
Approved
Investigational
Matched Description: … A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …

Bazedoxifene

Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the...
Approved
Investigational
Matched Description: … It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. ... In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the …
Matched Categories: … Genito Urinary System and Sex Hormones ... conjugated estrogens and bazedoxifene ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Hydroxyethyl Starch

Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.
Approved
Matched Description: … , concentration, C2/C6 ratio and Maximum Daily Dose. ... HES is a general term and can be sub-classified according to average molecular weight, molar substitution …
Matched Categories: … Blood and Related Products ... Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions ... Blood Substitutes and Plasma Protein Fractions …

Catumaxomab

Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites . Its market authorization was withdrawn in...
Approved
Investigational
Withdrawn
Matched Description: … It has affinity for T-cells, accessory immune cells, and cancer cells. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Alatrofloxacin

Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Approved
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid …

Cefamandole nafate

Approved
Matched Iupac: … methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Displaying drugs 2226 - 2250 of 14991 in total